CN101590200A - The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor - Google Patents
The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor Download PDFInfo
- Publication number
- CN101590200A CN101590200A CNA2008100551738A CN200810055173A CN101590200A CN 101590200 A CN101590200 A CN 101590200A CN A2008100551738 A CNA2008100551738 A CN A2008100551738A CN 200810055173 A CN200810055173 A CN 200810055173A CN 101590200 A CN101590200 A CN 101590200A
- Authority
- CN
- China
- Prior art keywords
- herba
- radix
- gained
- ligustri lucidi
- fructus ligustri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses the application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor.It is to be formed by Chinese medicine composition such as the Radix Astragali, Fructus Ligustri Lucidi.Each component of this pharmaceutical composition can produce synergism, by the evidence of animal pharmacodynamics, this medicine is applicable to the low leukocyte counts that primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor and a variety of causes cause and reduces the treatment of disease.Compatibility of the present invention is reasonable, and adverse effect is little, but the patients life-time service.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor, belong to the Chinese medicine application.
Background technology
Malignant tumor-cancer has become one of principal disease of common and serious threat human life and quality of life.According to 1997 years of World Health Organization (WHO), because of cancer mortality 6,300,000 people are arranged approximately in the whole world 5,800,000,000 populations in 1996, account for 12% of total death toll, wherein nearly 60% dies from pulmonary carcinoma, gastric cancer, breast carcinoma, colorectal carcinoma, oral cancer, hepatocarcinoma, cervical cancer and the esophageal carcinoma, and malignant tumor is the second largest cause of the death that is only second to cardiovascular disease.The annual tumor patient of newly making a definite diagnosis in the whole world is all more than 1,030 ten thousand people since 1996, to the end of the year 1999 whole world tumor patient sum exceeded 4,000 ten thousand people.World Health Organization's calendar year 2001 report, world's cancer morbidity and mortality rate have risen 22% than the nineteen ninety." report of world's tumor " that World Health Organization (WHO) delivers in April, 2004 says that a few years from now on will be the global tumor time occurred frequently, and sickness rate will increase by 50%, will increase by 1,500 ten thousand cases every year to the year two thousand twenty.
The Western medicine toxic and side effects of the treatment tumor of present clinical use is big, and the health to tumor patient in treatment also causes great injury.Chinese medicine has manifested it and has had the toxic and side effects of chemoradiotherapy of alleviating in antitumor, improve the effect of tumor patient life quality.But present antineoplastic herbal medicine efficacy material and curative effect are still not too clear and definite, and quality control index is not strict etc., make Chinese medicine be very limited in treatment is used, and have not met the modernization of Chinese medicine and have moved towards international requirement.In view of the foregoing, seek effective medicine that the medical material compatibility is reasonable, therapeutic effect is desirable, have no side effect and become current clinical treatment tumour urgent problem.
The present invention is the improvement invention of carrying out on No. 200410012347.4 basis, quotes in full the content of this patent document record at this.Unexposed this Chinese medicine composition of above-mentioned patent is in the human body immunity improving function, the application of strengthening spleen, tonifying kidney.The present invention has carried out correlational study on its basis, and the application of this Chinese medicine composition in preparation medicine for treating tumor thing is provided.
Summary of the invention
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in preparation medicine for treating tumor thing.
Chinese medicine of the present invention can be had the Chinese medicine of same or similar effect to replace, and these medical materials all can be concocted according to " national Chinese medicine processing standard " or " Chinese medicine voluminous dictionary ".This Chinese medicine composition is to be made by the crude drug of following weight portion ratio:
Radix Astragali 120-360 Fructus Ligustri Lucidi 100-300 Radix Ginseng 30-95 Ganoderma 30-95
Rhizoma Curcumae 65-195 Rhizoma Atractylodis Macrocephalae 30-90 Herba Scutellariae Barbatae 65-195 Herb Gynostemmae Pentaphylli 120-360
Poria 30-95 Endothelium Corneum Gigeriae Galli 15-45 Herba Duchesneae Indicae 65-195 Herba Solani Lyrati 65-195
Herba Artemisiae Scopariae 65-195 Radix Cynanchi Paniculati 65-195 Eupolyphaga Seu Steleophaga 10-30 Herba Hedyotidis Diffusae 65-195
Preferably, this Chinese medicine composition is made by following bulk drugs:
The Radix Astragali 120 Fructus Ligustri Lucidi 300 Radix Ginsengs 30 Ganodermas 95 Rhizoma Curcumae 65
The Rhizoma Atractylodis Macrocephalae 90 Herba Scutellariae Barbataes 65 Herb Gynostemmae Pentaphylli 360 Poria 30 Endothelium Corneum Gigeriae Galli 45
Herba Duchesneae Indicae 65 Herba Solani Lyratis 195 Herba Artemisiae Scopariaes 65 Radix Cynanchi Paniculatis 195
Eupolyphaga Seu Steleophaga 10 Herba Hedyotidis Diffusaes 195
Or
The Radix Astragali 360 Fructus Ligustri Lucidi 100 Radix Ginsengs 95 Ganodermas 30 Rhizoma Curcumae 195
The Rhizoma Atractylodis Macrocephalae 30 Herba Scutellariae Barbataes 195 Herb Gynostemmae Pentaphylli 120 Poria 95 Endothelium Corneum Gigeriae Galli 15
Herba Duchesneae Indicae 195 Herba Solani Lyratis 65 Herba Artemisiae Scopariaes 195 Radix Cynanchi Paniculatis 65
Eupolyphaga Seu Steleophaga 30 Herba Hedyotidis Diffusaes 65
Or
The Radix Astragali 250 Fructus Ligustri Lucidi 200 Radix Ginsengs 65 Ganodermas 65 Rhizoma Curcumae 132
The Rhizoma Atractylodis Macrocephalae 64 Herba Scutellariae Barbataes 128 Herb Gynostemmae Pentaphylli 256 Poria 65 Endothelium Corneum Gigeriae Galli 30
Herba Duchesneae Indicae 128 Herba Solani Lyratis 128 Herba Artemisiae Scopariaes 128 Radix Cynanchi Paniculatis 128
Herba Hedyotidis Diffusae 128 Eupolyphaga Seu Steleophagas 20
Preferably, in the raw materials used medicine of described Chinese medicine composition, the Rhizoma Atractylodis Macrocephalae is a Rhizoma Atractylodis Macrocephalae (parched).
The present invention also provides the active component of described Chinese medicine composition to be made by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Fructus Ligustri Lucidi, people participate in 6-10 and doubly measure the 50-90% ethanol extraction 1-3 time, each 1-4 hour, merge extractive liquid, filtered, filtrate recycling ethanol is not to there being the alcohol flavor, medicinal residues are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati add 4-8 times of water gaging and extract volatile oil, collects volatile oil, device is collected in addition, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, Poria powder are broken into fine powder;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (3), add 7-10 times of water gaging, heating decocts 1-3 time, each 1-3 hour, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into clear paste, drying is pulverized, and is standby;
The dried cream powder of step (4) gained comminuted powder, step (3) gained volatile oil and step (5) gained constitutes the active component of this Chinese medicine composition jointly.
The dosage form of medicine of the present invention is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray or injection.
The preparation method of capsule wherein is to be made by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati, united extraction volatile oil is carried the oil time and is no less than 8 hours, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli two flavor animal drugs, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, the sterilization back is standby;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (3), add 9 times of water gagings, heating decocts 2 times, each 2 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
Step (5) gained dried cream powder is added suitable acceptable accessories granulates;
(6), gained volatile oil in the step (3) is sprayed in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with the granule mixing of gained in the step (5), airtight half an hour, promptly encapsulated.
Other dosage forms of medicine of the present invention are in proportion after the weighting raw materials, adopt conventional preparation method preparation, for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
For above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
The objective of the invention is to the medicine that provides effective treatment tumor that a kind of medical material compatibility is reasonable, therapeutic effect is desirable, have no side effect for clinical.Pharmaceutical composition of the present invention has the effect of supplementing QI and nourishing YIN, strengthening spleen, tonifying kidney, resolving mass and removing the obstruction of the collateral, and the clinical tumor that is used for the treatment of has obtained good effect.Compatibility of the present invention is reasonable, and is simple, is pure Chinese medicinal preparation, and untoward reaction is little, but the patients life-time service.
The specific embodiment
Embodiment 1:
The crude drug prescription is:
Radix Astragali 250g Fructus Ligustri Lucidi 200g Radix Ginseng 65g Ganoderma 65g Rhizoma Curcumae 132g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 64g Herba Scutellariae Barbatae 128g Herb Gynostemmae Pentaphylli 256g Poria 65g Endothelium Corneum Gigeriae Galli 30g
Herba Duchesneae Indicae 128g Herba Solani Lyrati 128g Herba Artemisiae Scopariae 128g Radix Cynanchi Paniculati 128g
Herba Hedyotidis Diffusae 128g Eupolyphaga Seu Steleophaga 20g
Preparation method is:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae (stir-fry), Radix Cynanchi Paniculati, united extraction volatile oil is carried the 8 hours time of oil, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, in 3KGY
60Standby after the CO-r radiation sterilization;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried behind the oil in the step (3) residue and aqueous solution merge, and adds 9 times of water gagings, heating decocts 2 times, each 2 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
(6), step (5) gained dried cream powder is added starch 134 grams, use 85% alcohol granulation;
(7), with gained volatile oil 85% dissolve with ethanol in the step (3), spray in the fine powder of middle gained Poria of step poly-(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli mixing; granule mixing with gained in the step (6); airtight half an hour, pack 1000 capsules into promptly, hereinafter to be referred as JN.
Embodiment 2:
The crude drug prescription is:
Radix Astragali 360g Fructus Ligustri Lucidi 100g Radix Ginseng 95g Ganoderma 30g Rhizoma Curcumae 195g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 30g Herba Scutellariae Barbatae 195g Herb Gynostemmae Pentaphylli 120g Poria 95g Endothelium Corneum Gigeriae Galli 15g
Herba Duchesneae Indicae 195g Herba Solani Lyrati 65g Herba Artemisiae Scopariae 195g Radix Cynanchi Paniculati 65g
Eupolyphaga Seu Steleophaga 30g Herba Hedyotidis Diffusae 65g
Preparation method is:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 6 times of amount 90% alcohol reflux 4 hours, extracting solution reclaims ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae (stir-fry), Radix Cynanchi Paniculati merge, and adds 4 times of water gagings and extract volatile oil, carries the 10 hours time of oil, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, in 3KGY
60Standby after the CO-r radiation sterilization;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried behind the oil in the step (3) residue and aqueous solution merge, add 7 times of water gagings, heating decocts 3 times, 1 hour for the first time, 2 hours for the second time, 3 hours for the third time, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
(6), step (5) gained dried cream powder is added starch 134 grams, use 78% alcohol granulation;
(7), with gained volatile oil 85% dissolve with ethanol in the step (3); spray in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing is with the granule mixing of gained in the step (6); formulation method is made 1000 tablets of tablets routinely, hereinafter to be referred as PJ.
Embodiment 3:
The crude drug prescription is:
Radix Astragali 120g Fructus Ligustri Lucidi 300g Radix Ginseng 30g Ganoderma 95g Rhizoma Curcumae 65g
Rhizoma Atractylodis Macrocephalae 90g Herba Scutellariae Barbatae 65g Herb Gynostemmae Pentaphylli 360g Poria 30g Endothelium Corneum Gigeriae Galli 45g
Herba Duchesneae Indicae 65g Herba Solani Lyrati 195g Herba Artemisiae Scopariae 65g Radix Cynanchi Paniculati 195g
Eupolyphaga Seu Steleophaga 10g Herba Hedyotidis Diffusae 195g
Preparation method is:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 10 times of amount 50% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati merge, and adds 10 times of water gagings and extract volatile oil, carries the 6 hours time of oil, volatile oil device collection in addition, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, in 3KGY
60Standby after the CO-r radiation sterilization;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), reach residue and the aqueous solution that gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried behind the oil in the step (3) and merge, add 10 times of water gagings, heating decocted 3 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying, pulverize, standby;
(6), step (5) gained dried cream powder is added starch 115 grams, use 80% alcohol granulation;
(7), with gained volatile oil 80% dissolve with ethanol in the step (3), spray in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with the fine powder of the middle gained of step (6), formulation method is made 1000 ball pills routinely, hereinafter to be referred as WJ.
Embodiment 4:
The crude drug prescription is:
Radix Astragali 250g Fructus Ligustri Lucidi 200g Radix Ginseng 65g Ganoderma 65g Rhizoma Curcumae 132g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 64g Herba Scutellariae Barbatae 128g Herb Gynostemmae Pentaphylli 256g Poria 65g Endothelium Corneum Gigeriae Galli 30g
Herba Duchesneae Indicae 128g Herba Solani Lyrati 128g Herba Artemisiae Scopariae 128g Radix Cynanchi Paniculati 128g
Herba Hedyotidis Diffusae 128g Eupolyphaga Seu Steleophaga 20g
Preparation method is: preparation method is made powder routinely.
Embodiment 5:
The crude drug prescription is:
Radix Astragali 360g Fructus Ligustri Lucidi 100g Radix Ginseng 95g Ganoderma 30g Rhizoma Curcumae 195g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 30g Herba Scutellariae Barbatae 195g Herb Gynostemmae Pentaphylli 120g Poria 95g Endothelium Corneum Gigeriae Galli 15g
Herba Duchesneae Indicae 195g Herba Solani Lyrati 65g Herba Artemisiae Scopariae 195g Radix Cynanchi Paniculati 65g
Eupolyphaga Seu Steleophaga 30g Herba Hedyotidis Diffusae 65g
Preparation method is: preparation method is made soft capsule routinely.
Embodiment 6:
The crude drug prescription is:
Radix Astragali 120g Fructus Ligustri Lucidi 300g Radix Ginseng 30g Ganoderma 95g Rhizoma Curcumae 65g
Rhizoma Atractylodis Macrocephalae 90g Herba Scutellariae Barbatae 65g Herb Gynostemmae Pentaphylli 360g Poria 30g Endothelium Corneum Gigeriae Galli 45g
Herba Duchesneae Indicae 65g Herba Solani Lyrati 195g Herba Artemisiae Scopariae 65g Radix Cynanchi Paniculati 195g
Eupolyphaga Seu Steleophaga 10g Herba Hedyotidis Diffusae 195g
Preparation method is: preparation method is made oral liquid routinely.
Embodiment 7:
The crude drug prescription is:
Radix Astragali 250g Fructus Ligustri Lucidi 200g Radix Ginseng 65g Ganoderma 65g Rhizoma Curcumae 132g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 64g Herba Scutellariae Barbatae 128g Herb Gynostemmae Pentaphylli 256g Poria 65g Endothelium Corneum Gigeriae Galli 30g
Herba Duchesneae Indicae 128g Herba Solani Lyrati 128g Herba Artemisiae Scopariae 128g Radix Cynanchi Paniculati 128g
Herba Hedyotidis Diffusae 128g Eupolyphaga Seu Steleophaga 20g
Preparation method is: preparation method is made tincture routinely.
Embodiment 8:
The crude drug prescription is:
Radix Astragali 360g Fructus Ligustri Lucidi 100g Radix Ginseng 95g Ganoderma 30g Rhizoma Curcumae 195g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 30g Herba Scutellariae Barbatae 195g Herb Gynostemmae Pentaphylli 120g Poria 95g Endothelium Corneum Gigeriae Galli 15g
Herba Duchesneae Indicae 195g Herba Solani Lyrati 65g Herba Artemisiae Scopariae 195g Radix Cynanchi Paniculati 65g
Eupolyphaga Seu Steleophaga 30g Herba Hedyotidis Diffusae 65g
Preparation method is: preparation method is made syrup routinely.
Embodiment 9:
The crude drug prescription is:
Radix Astragali 120g Fructus Ligustri Lucidi 300g Radix Ginseng 30g Ganoderma 95g Rhizoma Curcumae 65g
Rhizoma Atractylodis Macrocephalae 90g Herba Scutellariae Barbatae 65g Herb Gynostemmae Pentaphylli 360g Poria 30g Endothelium Corneum Gigeriae Galli 45g
Herba Duchesneae Indicae 65g Herba Solani Lyrati 195g Herba Artemisiae Scopariae 65g Radix Cynanchi Paniculati 195g
Eupolyphaga Seu Steleophaga 10g Herba Hedyotidis Diffusae 195g
Preparation method is: preparation method is made suppository routinely.
Embodiment 10:
The crude drug prescription is:
Radix Astragali 250g Fructus Ligustri Lucidi 200g Radix Ginseng 65g Ganoderma 65g Rhizoma Curcumae 132g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 64g Herba Scutellariae Barbatae 128g Herb Gynostemmae Pentaphylli 256g Poria 65g Endothelium Corneum Gigeriae Galli 30g
Herba Duchesneae Indicae 128g Herba Solani Lyrati 128g Herba Artemisiae Scopariae 128g Radix Cynanchi Paniculati 128g
Herba Hedyotidis Diffusae 128g Eupolyphaga Seu Steleophaga 20g
Preparation method is: preparation method is made gel routinely.
Embodiment 11:
The crude drug prescription is:
Radix Astragali 360g Fructus Ligustri Lucidi 100g Radix Ginseng 95g Ganoderma 30g Rhizoma Curcumae 195g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 30g Herba Scutellariae Barbatae 195g Herb Gynostemmae Pentaphylli 120g Poria 95g Endothelium Corneum Gigeriae Galli 15g
Herba Duchesneae Indicae 195g Herba Solani Lyrati 65g Herba Artemisiae Scopariae 195g Radix Cynanchi Paniculati 65g
Eupolyphaga Seu Steleophaga 30g Herba Hedyotidis Diffusae 65g
Preparation method is: preparation method is made spray routinely.
Embodiment 12:
The crude drug prescription is:
Radix Astragali 120g Fructus Ligustri Lucidi 300g Radix Ginseng 30g Ganoderma 95g Rhizoma Curcumae 65g
Rhizoma Atractylodis Macrocephalae 90g Herba Scutellariae Barbatae 65g Herb Gynostemmae Pentaphylli 360g Poria 30g Endothelium Corneum Gigeriae Galli 45g
Herba Duchesneae Indicae 65g Herba Solani Lyrati 195g Herba Artemisiae Scopariae 65g Radix Cynanchi Paniculati 195g
Eupolyphaga Seu Steleophaga 10g Herba Hedyotidis Diffusae 195g
Preparation method is: preparation method is made injection routinely.
For confirming the curative effect of Drug therapy tumor of the present invention, with the pharmaceutical composition of the present invention that makes by embodiment, carried out following animal pharmacodynamics test, prove that this medicine sets upright in the body QI invigorating, be applicable to the low leukocyte counts that primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor and a variety of causes cause and reduce disease, chronic viral hepatitis B is had excellent curative.
Embodiment 4:
Pharmaceutical composition of the present invention is to the influence of S180 sarcoma
1.1 animal SPF level BALB/c mouse is got 70 of kunming mices, male and female half and half, and male and female half and half, age in 6-8 week, body weight 18～22g, normal water inlet diet is 7 days before the experiment.
1.2 medicine and reagent pharmaceutical composition of the present invention, JN, PJ, WJ with embodiment makes are provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd.Control drug is the compound fluorouracil injection, and Pharmaceutical Factory, Bethune Medical Univ. produces, lot number: 071004.
1.3 aseptic tumor source of getting the S180 sarcoma, S180 sarcoma 1 * 10
7/ ml cell suspension, every Mus oxter inoculation 0.2ml.Inoculate and begin administration after 24 hours, 1 time/day, continuous 10 days; Mice finish is put to death in administration, and to get the solid tumor comparison administration group of weighing different with the model group tumor method of double differences, the calculating tumour inhibiting rate.
The tumour inhibiting rate computing formula:
Tumour inhibiting rate (%)=[(it is heavy that average tumor is organized in the average tumor weight-treatment of blank group)]/average tumor of blank group heavy * 100%
1.4 result
Table 1 pharmaceutical composition of the present invention is to the influence of S180 sarcoma
| Group | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Blank | 1.34±0.65 | |
| Matched group | 0.25±0.36** | 84 |
| The JN group | 0.65±0.46** | 58 |
| The PJ group | 0.67±0.43** | 54 |
| The WJ group | 0.67±0.40** | 49 |
Compare * * P＜0.05 with the blank group
Embodiment 5
Pharmaceutical composition of the present invention is to the influence of Lewis lung cancer
Get 70 of C57BL/6 mices, male and female half and half, normal water inlet diet is 7 days before the experiment.Aseptic tumor source of getting Lewis lung cancer is in the every Mus of C57BL/6 mice oxter inserted block inoculation 1mm
3Inoculate and begin administration after 24 hours, 1 time/day, continuous 12 days.Mice finish is put to death in administration, and to get the solid tumor comparison administration group of weighing different with the model group tumor method of double differences, the calculating tumour inhibiting rate.
The tumour inhibiting rate computing formula:
Tumour inhibiting rate (%)=[(it is heavy that average tumor is organized in the average tumor weight-treatment of blank group)]/average tumor of blank group heavy * 100%
Table 2 pharmaceutical composition of the present invention is to the influence of Lewis lung cancer
| Group | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Blank | 1.23±0.52 | |
| Matched group | 0.28±0.31** | 80 |
| The JN group | 0.62±0.31** | 52 |
| The PJ group | 0.64±0.35** | 48 |
| The WJ group | 0.57±0.22** | 46 |
Compare * * P＜0.05 with the blank group
Embodiment 6
Pharmaceutical composition of the present invention is to the leukocytic influence of chemotherapy tumor-bearing mice
With transplanting 8-10 days well-grown hepatoma carcinoma cell, make the cancerous cell suspension with normal saline in 1: 3 ratio, be seeded in the mice oxter behind the routine disinfection, every 0.2ml.Every day, every injected in mice ring phosphorus phthalein amine 20mg/kg irritated each medicine of stomach simultaneously respectively, continuous 10 days, raised after the drug withdrawal 10 days again.Respectively in medication 5 days, medication 10 days, drug withdrawal 5 days, drug withdrawal 10 days are got 10 tumor-bearing mices for every group and are made the tail vein and get blood, survey the peripheral leukocytes sum, weigh.
As a result, obvious decline (P＜0.05) appears in model group leukocyte count by statistics, and the leukopenia phenomenon of each dosage group of pharmaceutical composition of the present invention is all not remarkable, and each dosage group of pharmaceutical composition of the present invention and model group differences be (P＜0.05) significantly.
Embodiment 7
Influence to mice ehrlich carcinoma and ascitic type liver cancer H22
Kunming mouse abdominal cavity inoculation ehrlich ascites tumor liquid (EAC) or H22 oncocyte 0.5ml/ only, random packet after 24 hours is weighed, intravenously administrable, once a day, continuous 7 days.Observe the mice survival rate after the drug withdrawal.The result shows with matched group and compares that each dosage group of pharmaceutical composition of the present invention all can significant prolongation mice survival rate (p＜0.05).
Embodiment 8
Protective effect to acute liver damage due to the carbon tetrachloride
Blister rat oral gavage pharmaceutical composition of the present invention, after continuous 5 days, lumbar injection 0.1% 4 carbonoxide 10ml/kg causes the acute liver damage model, measure animal serum ALT, AST level after 24 hours, the result shows: each dosed administration group Serum ALT of pharmaceutical composition of the present invention, the AST level obviously reduces (P＜0.05) than normal saline model control group rising amplitude.Through the liver histological pathological observation, the hepatic injury zone has obviously and dwindles.
Embodiment 9
Choleretic effect
Rat is irritated stomach pharmaceutical composition of the present invention or normal saline contrast, continuous 1 week respectively.After the last administration second day, the abdominal cavity is opened in operation behind the rat anesthesia, carry out the common bile duct intubate, bile drainage writes down the bile milliliter number of drain in per ten minutes.Irritate stomach pharmaceutical composition of the present invention then, the bile amount of record drain.The result shows: can improve the rat bile secretory volume with normal saline matched group comparison injection of the present invention, have obvious choleretic effect.
Claims (8)
1, the application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor is characterized in that being that the crude drug of following weight portion ratio is made:
Radix Astragali 120-360 Fructus Ligustri Lucidi 100-300 Radix Ginseng 30-95 Ganoderma 30-95
Rhizoma Curcumae 65-195 Rhizoma Atractylodis Macrocephalae 30-90 Herba Scutellariae Barbatae 65-195 Herb Gynostemmae Pentaphylli 120-360
Poria 30-95 Endothelium Corneum Gigeriae Galli 15-45 Herba Duchesneae Indicae 65-195 Herba Solani Lyrati 65-195
Herba Artemisiae Scopariae 65-195 Radix Cynanchi Paniculati 65-195 Eupolyphaga Seu Steleophaga 10-30 Herba Hedyotidis Diffusae 65-195.
2, application according to claim 1 is characterized in that being made by following bulk drugs:
The Radix Astragali 120 Fructus Ligustri Lucidi 300 Radix Ginsengs 30 Ganodermas 95 Rhizoma Curcumae 65 Rhizoma Atractylodis Macrocephalaes 90
Herba Scutellariae Barbatae 65 Herb Gynostemmae Pentaphylli 360 Poria 30 Endothelium Corneum Gigeriae Galli 45 Herba Duchesneae Indicaes 65
Herba Solani Lyrati 195 Herba Artemisiae Scopariaes 65 Radix Cynanchi Paniculatis 195 Eupolyphaga Seu Steleophagas 10 Herba Hedyotidis Diffusaes 195.
3, application according to claim 1 is characterized in that being made by following bulk drugs:
The Radix Astragali 360 Fructus Ligustri Lucidi 100 Radix Ginsengs 95 Ganodermas 30 Rhizoma Curcumae 195 Rhizoma Atractylodis Macrocephalaes 30
Herba Scutellariae Barbatae 195 Herb Gynostemmae Pentaphylli 120 Poria 95 Endothelium Corneum Gigeriae Galli 15 Herba Duchesneae Indicaes 195
Herba Solani Lyrati 65 Herba Artemisiae Scopariaes 195 Radix Cynanchi Paniculatis 65 Eupolyphaga Seu Steleophagas 30 Herba Hedyotidis Diffusaes 65.
4, application according to claim 1 is characterized in that being made by following bulk drugs:
The Radix Astragali 250 Fructus Ligustri Lucidi 200 Radix Ginsengs 65 Ganodermas 65 Rhizoma Curcumae 132 Rhizoma Atractylodis Macrocephalaes 64
Herba Scutellariae Barbatae 128 Herb Gynostemmae Pentaphylli 256 Poria 65 Endothelium Corneum Gigeriae Galli 30 Herba Duchesneae Indicaes 128
Herba Solani Lyrati 128 Herba Artemisiae Scopariaes 128 Radix Cynanchi Paniculatis 128 Herba Hedyotidis Diffusaes 128 Eupolyphaga Seu Steleophagas 20.
5,, it is characterized in that the described Rhizoma Atractylodis Macrocephalae is a Rhizoma Atractylodis Macrocephalae (parched) according to each described application of claim 1-4.
6, according to each described application of claim 1-4, it is characterized in that the active component of described Chinese medicine composition is made by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Fructus Ligustri Lucidi, people participate in 6-10 and doubly measure the 50-90% ethanol extraction 1-3 time, each 1-4 hour, merge extractive liquid, filtered, filtrate recycling ethanol is not to there being the alcohol flavor, medicinal residues are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati add 4-8 times of water gaging and extract volatile oil, collects volatile oil, device is collected in addition, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, Poria powder are broken into fine powder;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (3), add 7-10 times of water gaging, heating decocts 1-3 time, each 1-3 hour, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into clear paste, drying is pulverized, and is standby;
The dried cream powder of step (4) gained comminuted powder, step (3) gained volatile oil and step (5) gained constitutes the active component of this Chinese medicine composition jointly.
7,, it is characterized in that described pharmaceutical dosage form is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray or injection according to each described application of claim 1-4.
8,, it is characterized in that it being to make by following steps according to the preparation method of the described medicine capsule of claim 7:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati, united extraction volatile oil is carried the oil time and is no less than 8 hours, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli two flavor animal drugs, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, the sterilization back is standby;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (3), add 9 times of water gagings, heating decocts 2 times, each 2 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
Step (5) gained dried cream powder is added suitable acceptable accessories granulates;
(6), gained volatile oil in the step (3) is sprayed in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with in the step (5) in the granule mixing of gained, airtight half an hour, promptly encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100551738A CN101590200A (en) | 2008-05-29 | 2008-05-29 | The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100551738A CN101590200A (en) | 2008-05-29 | 2008-05-29 | The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210078759.2A Division CN102580002B (en) | 2008-05-29 | 2008-05-29 | Application of Chinese medicinal composition to preparation of medicines for treating acute liver injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101590200A true CN101590200A (en) | 2009-12-02 |
Family
ID=41405200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100551738A Pending CN101590200A (en) | 2008-05-29 | 2008-05-29 | The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590200A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284040A (en) * | 2011-09-08 | 2011-12-21 | 鲍修惠 | Composition medicament for treating tumor |
| WO2013071727A1 (en) * | 2011-11-14 | 2013-05-23 | Fan Shenggang | Anti-tumor traditional chinese medical composition |
| CN103386078A (en) * | 2012-05-12 | 2013-11-13 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicinal composition in preparation of medicines for treating colon cancer |
| CN103417907A (en) * | 2012-05-26 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis |
| CN103830662A (en) * | 2012-05-26 | 2014-06-04 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of drug for inhibiting rheumatoid arthritis angiogenesis |
| WO2014176934A1 (en) * | 2013-05-02 | 2014-11-06 | 河北以岭医药研究院有限公司 | Use of traditional chinese medicine composition in preparation of drugs for treating or preventing angiogenesis related diseases |
| CN104324316A (en) * | 2013-07-22 | 2015-02-04 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer |
| CN105126030A (en) * | 2015-09-25 | 2015-12-09 | 广西中医药大学 | Zhuang medicine composition assisted in resisting lung cancer |
| CN105288492A (en) * | 2015-11-30 | 2016-02-03 | 秦朝阳 | Traditional Chinese medicine preparation for rectal cancer and preparation method thereof |
| CN106578199A (en) * | 2016-12-16 | 2017-04-26 | 横琴智库转化医学有限公司 | Oral solution for preventing malignant tumors |
| CN109419979A (en) * | 2017-08-22 | 2019-03-05 | 曾令元 | A kind of Chinese medicine composition that treating intestinal cancer and preparation method |
-
2008
- 2008-05-29 CN CNA2008100551738A patent/CN101590200A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284040B (en) * | 2011-09-08 | 2013-11-20 | 鲍修惠 | Composition medicament for treating tumor |
| CN102284040A (en) * | 2011-09-08 | 2011-12-21 | 鲍修惠 | Composition medicament for treating tumor |
| WO2013071727A1 (en) * | 2011-11-14 | 2013-05-23 | Fan Shenggang | Anti-tumor traditional chinese medical composition |
| CN103386078A (en) * | 2012-05-12 | 2013-11-13 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicinal composition in preparation of medicines for treating colon cancer |
| CN103386078B (en) * | 2012-05-12 | 2017-11-17 | 石家庄以岭药业股份有限公司 | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug |
| CN103830662B (en) * | 2012-05-26 | 2017-09-26 | 石家庄以岭药业股份有限公司 | A kind of application of Chinese medicine composition in treatment medicine for treating rheumatoid arthritis is prepared |
| CN103417907A (en) * | 2012-05-26 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis |
| CN103830662A (en) * | 2012-05-26 | 2014-06-04 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of drug for inhibiting rheumatoid arthritis angiogenesis |
| WO2014176934A1 (en) * | 2013-05-02 | 2014-11-06 | 河北以岭医药研究院有限公司 | Use of traditional chinese medicine composition in preparation of drugs for treating or preventing angiogenesis related diseases |
| CN104324316A (en) * | 2013-07-22 | 2015-02-04 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer |
| CN105126030A (en) * | 2015-09-25 | 2015-12-09 | 广西中医药大学 | Zhuang medicine composition assisted in resisting lung cancer |
| CN105126030B (en) * | 2015-09-25 | 2019-02-05 | 广西中医药大学 | A kind of strong drug composition assisting anti-lung cancer |
| CN105288492A (en) * | 2015-11-30 | 2016-02-03 | 秦朝阳 | Traditional Chinese medicine preparation for rectal cancer and preparation method thereof |
| CN106578199A (en) * | 2016-12-16 | 2017-04-26 | 横琴智库转化医学有限公司 | Oral solution for preventing malignant tumors |
| CN109419979A (en) * | 2017-08-22 | 2019-03-05 | 曾令元 | A kind of Chinese medicine composition that treating intestinal cancer and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101590200A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor | |
| CN104491751A (en) | Traditional Chinese medicine composition for treating fatty liver combined with hyperlipidemia and preparation method of traditional Chinese medicine composition | |
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN102210836A (en) | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer | |
| CN1935194B (en) | Preparation method of Chinese medicine composition for treating nephroma | |
| CN102988875A (en) | Medicinal composition for treating fatty liver, and its preparation method | |
| CN110856741A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN102908443B (en) | Medicinal composition for therapy or adjuvant therapy of aids, preparation method of medicinal composition and application of medicinal composition | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN102028924A (en) | Medicinal composition for late gastric cancer | |
| CN102038821B (en) | Method for preparing medicinal composition for treating dysmenorrhea | |
| CN102580002B (en) | Application of Chinese medicinal composition to preparation of medicines for treating acute liver injury | |
| CN102430008B (en) | Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN112206298A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea | |
| CN101513508A (en) | Chinese medicament for treating breast cancer, and preparation method thereof | |
| CN101683421B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating repetitive respiratory tract infection | |
| CN101259180B (en) | Shenshe composition and preparation thereof | |
| CN101579495B (en) | Application of Chinese medicine composite in preparation of medicine for treating chronic gastritis | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN1830482B (en) | Chinese medicinal composition and application for treating child pneumonia for treating | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
| CN1814193B (en) | Chinese medicine composition for treating nephritis dropsy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091202 |